Platelet activation and responsiveness in patients with acute exacerbations of chronic obstructive pulmonary disease (AE-COPD)

Completed

• Conditions: COPD - obstructive lung disease; 10011082; 10006436

• Registration Number: NL-OMON45449
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

In order to be eligible to participate in this study the COPD subjects must meet all of the following criteria:
* >40 years
* Spirometry confirmed diagnosis of COPD (i.e. post-bronchodilator FEV1/FVC < Lower limit of normal (LLN)).
* *10 pack years of smoking

Exclusion Criteria

* Use of anti-coagulation, aspirin or platelet function inhibitors, with the exception of cyclooxygenase inhibitors (e.g, carbasalate calcium, acetylsalicylic acid)
* Asthma
* Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases , systemic lupus erythematous (SLE)
* Malignancies

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1/2) Platelet activation: platelet expression of the platelet activation marker<br /><br>CD62P (P-selectin) and binding of fibrinogen to the activated fibrinogen<br /><br>receptor (*IIb*3) at baseline and upon stimulation with different platelet<br /><br>agonists. 3) Platelet-monocyte complexes. 4) Tissue factor (TF) triggered<br /><br>thrombin generation. 5) Soluble (plasma) markers of platelet activation and<br /><br>inflammatory cytokines. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Please see the section primary study parameters</p><br>